Updated Educational Risk Minimisation Materials for Opsumit (macitentan) 10 mg Film-coated Tablets

These risk management materials provide information on recommended safe use and safety monitoring requirements and have been updated in line with latest SPC. They cover women of childbearing potential, patients with severe anaemia and monitoring for signs of hepatic injury.

Source:

Janssen-Cilag Ltd